Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.68 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.62 |
| ▸ | P4HB | P07237 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80571 | 1.00 | CYP1A2 (0.75) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| Hydrochloric Acid SCHEMBL6510827 | 0.98 | CYP1A2 (0.72) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| Hydrochloric Acid SCHEMBL27760116 | 0.98 | CYP1A2 (0.72) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6845616 | 0.91 | CYP1A2 (0.64) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6845622 | 0.91 | CYP1A2 (0.64) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6845615 | 0.91 | CYP1A2 (0.64) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL10467114 | 0.89 | CYP1A2 (0.83) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL10467116 | 0.89 | CYP1A2 (0.83) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL30662308 | 0.88 | HDAC3 (0.63) | CYP1A2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5572624 | 0.87 | CYP1A2 (0.62) | CYP1A2HDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132052-A1 | NANOPARTICLE, AND INK COMPOSITION, LIGHT-EMITTING DEVICE, ELECTRONIC APPARATUS AND ELECTRONIC DEVICE, INCLUDING THE NANOPARTICLE | SAMSUNG DISPLAY CO LTD (KR) | 2026-05-14 | — | — | US | claimed |
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | claimed |
| CN-119371372-A | Bcr-Abl targeting molecular gel and preparation method and application thereof | 中山大学 | 2025-01-28 | — | — | CN | claimed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | claimed |
| CN-109896684-B | Sewage pretreatment process in organic product preparation process | 李德祥 | 2021-12-24 | — | — | CN | claimed |
| CN-112920133-A | (E) -4-methyl-2- (4- (trifluoromethyl) styryl) oxazole compound and preparation method and application thereof | 中国医科大学 | 2021-06-08 | — | — | CN | claimed |
| WO-2020252075-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-12-17 | — | — | WO | claimed |
| CN-111018735-A | Preparation method of cinnamamide | 河南农业大学 | 2020-04-17 | — | — | CN | claimed |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2020-01-28 | — | — | US | claimed |
| CN-109896684-A | A kind of pre-treating process for sewage in organic products preparation process | 李德祥 | 2019-06-18 | — | — | CN | claimed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0612734-A1 | Novel orally active antifungal agents | J. URIACH & CIA. S.A. (ES) | 1994-08-31 | — | — | EP | claimed |
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132052-A1 | NANOPARTICLE, AND INK COMPOSITION, LIGHT-EMITTING DEVICE, ELECTRONIC APPARATUS AND ELECTRONIC DEVICE, INCLUDING THE NANOPARTICLE | L1CAM, LASP1, CD63 | CYP1A2 728/4885HDAC3 3946/4885HDAC1 2969/4885 |
| US-10544168-B2 | Ligand-exchangeable nanoparticles and methods of making the same | CA6, CA13, EPCAM | CYP1A2 432/4885HDAC3 2613/4885HDAC1 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.